352
Participants
Start Date
July 28, 2023
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2026
Sutezolid
Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
N-acetyl cysteine
NAC will be given at a dose of 1800 mg BID in arm 3
Pretomanid
Pretomanid will be given at its approved dose
Bedaquiline
Bedaquiline will be given at its approved dose
Rifafour
Fixed dose combination tablets for TB treatment will be given at approved doses
The Aurum Institute: Tembisa Clinical Research Centre, Tembisa
Clinical HIV Research Unit, Johannesburg
The Aurum Institute, Gavin J Churchyard Legacy Centre (Klerksdorp Clinical Research Centre), Klerksdorp
Clinical HIV Research Unit, Durban
TASK Eden, George
Instituto Nacional de Saúde, Maputo
NIMR-Mbeya Medical Research Centre, Mbeya
The Aurum Institute, Rustenburg Clinical Research Centre, Rustenburg
Ludwig-Maximilians - University of Munich
OTHER
Stichting Katholieke Universiteit
OTHER
Wits Health Consortium (Pty) Ltd
OTHER
Instituto Nacional de Saúde, Mozambique
OTHER_GOV
National Institute for Medical Research, Tanzania
OTHER_GOV
University of Stellenbosch
OTHER
Sequella, Inc.
INDUSTRY
Global Alliance for TB Drug Development
OTHER
The Aurum Institute NPC
OTHER